Live feed07:00:00·661dPRReleasevia QuantisnowAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationByQuantisnow·Wall Street's wire, on your screen.AMLX· Amylyx Pharmaceuticals Inc.Health Care
